Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001803671 | SCV002049945 | pathogenic | Hereditary factor VIII deficiency disease | 2021-01-15 | criteria provided, single submitter | clinical testing | The F8 c.5335G>A; p.Gly1779Arg variant (rs1168919288) is reported in the literature in multiple individuals affected with severe hemophilia A (see F8 database and references therein). In vitro functional analyses demonstrate that individuals with this variant have factor VIII activity of <1% (F8 database). Additionally, another variant resulting in the same amino acid change (c.5335G>C, p.Gly1779Arg) has been observed in an individual with severe hemophilia A (Johnsen 2017). This variant is absent from general population databases (Exome Variant Server, Genome Aggregation Database), indicating it is not a common polymorphism. Furthermore, another variant at this codon (c.5336A>G, p.Gly1779Glu) has been reported in individuals with severe hemophilia A and is considered pathogenic (Johnsen 2017). The glycine at codon 1779 is highly conserved, and computational analyses predict that this variant is deleterious (REVEL: 0.992). Based on available information, the c.5335G>A; p.Gly1779Arg variant is considered to be pathogenic. References: Link to F8 database: https://f8-db.eahad.org/ Johnsen JM et al. Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative. Blood Adv. 2017 May 18;1(13):824-834. |